丙型肝炎直接抗病毒治疗研究进展

doi:10.3969/j.issn.1672-5069.2016.04.002

Abstract

Rao Huiying. Directly acting antiviral agents in hepatitis C[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(4): 390-393.

[1] Fontanges T. Management of treatment with direct-acting antiviral（DAA） in clinical practice. Clin Res Hepatol Gastroenterol,2011,35（Suppl 2）:S64-S68.
[2] Moradpour D,Penin F,Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol,2007,5（6）:453-463.
[3] Penin F,Dubuisson J,Rey FA,et al. Structural biology of hepatitis C virus. Hepatology,2004,39（1）:5-19.
[4] Foy E,Li K,Wang C,et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science, 2003,300（5622）:1145-1148.
[5] Burton JR Jr,Everson GT. HCV NS5B polymerase inhibitors. Clin Liver Dis,2009,13（3）:453-465.
[6] European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol,2015,63（1）:199-236.
[7] Rao H,Wei L,Lopez-Talavera JC,et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol,2014,29（3）:545-553.
[8] Wei L,Han T,Yang D,et al. Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naive patients in China and South Korea. J Gastroenterol Hepatol,2016,31（5）:912-920.
[9] Kumada H,Suzuki Y,Ikeda K,et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology, 2014,59（6）:2083-2091.
[10] Wei L,Zhang M,Xu M,et al. A phase 3,open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin . J Gastroenterol Hepatol,2016,doi:10.1111/jgh.13379.
[11] Lawitz E,Mangia A,Wyles D,et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med,2013,368（20）:1878-1887.
[12] Mishra P,Florian J,Qi K,et al. FDA perspective on sofosbuvir therapy for patients with chronic hepatitis C virus genotype 1 infection who did not respond to treatment with pegylated interferon and ribavirin. Gastroenterology,2014,147（6）:1196-1200.
[13] Zeuzem S,Dusheiko GM,Salupere R,et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med,2014,370（21）:1993-2001.
[14] Lawitz E,Sulkowski MS,Ghalib R,et al. Simeprevir plus sofosbuvir,with or without ribavirin,to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients:the COSMOS randomised study. Lancet,2014,384（9956）:1756-1765.

[1]	Pan Meimin, Li Wenjuan, Jiang Fangqing, et al.. Changes of serum IL-17A,fibroblast growth factor and IL-7 levels in patients with hepatitis C virus infection [J]. Journal of Practical Hepatology, 2019, 22(6): 840-843.
[2]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[3]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[4]	Deng Haohui, Li Xiaoqiang, Gao Hongbo, et al. Comparison of HCV genotypes in patients with HIV/HCV co-infection and HCV mono-infection in Guangzhou [J]. Journal of Practical Hepatology, 2019, 22(5): 656-659.
[5]	Liu Li，Li Junyi，Du Yingrong. Efficacy and safety of sofosbuvir/daclatasvir in the treatment of patients with chronic hepatitis C and hepatitis C cirrhosis:An real-world study [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 361-364.
[6]	Jiang Yi, Liu Bing. Comparison of clinical features and histopathological activity index between patients with chronic hepatitis B and chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 188-191.
[7]	Wu Jing, Dong Baoji, Wu Chao. Comparison of PD-1 receptor on peripheral blood follicular helper T lymphocyte surface in chronic hepatitis C patients with low and high serum viral loads [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 192-195.
[8]	Wu Yaping, Zhou Bingqing, Jiang Peili. Risk factors of severe hepatic fibrosis in patients with chronic hepatitis C with previous paid blood donation [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 196-199.
[9]	Yang Zhenjie, Li Hongtao, Wang Jian, Li Xia, Chen Yuan. Efficacy of combination of pegylated interferon-α-2a and ribavirin in treatment of patients with compensated hepatitis C cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 232-235.
[10]	Hou Chunyang, Ma Yumei, Li Fangzhi.. Clinical efficacy of peg-IFNα and ribavirin combination in treating patients with chronic hepatitis C and genotype one and six infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 53-56.
[11]	Zhao Peng, Wang Lei.. Comparison of therapeutic efficacy of pegylated interferon-α in treatment of patients with different hepatitis C viral genotype infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 57-60.
[12]	Xu Xi, Dang Yinli, Wu Shuo.. Construction and expression of recombinant eukaryotic expression vector of HCV infection related interferon λ4 [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 833-836.
[13]	Ji Xiaoqin, Gong Jian.. Clinical features and antiviral treatment of elderly patients with chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 995-998.
[14]	Zhou Sisi, Shen Youxiu, Li Juan, et al.. Changes of peripheral blood Th17 and Treg cells and their related serum cytokines in patients with chronic hepatitis C and liver cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 689-692.
[15]	Cao Fenghua, Jing Jisheng, Zhao Wei, et al.. Clinical efficacy and safety of large dose of domestic interferon-α2b and ribavirin in the treatment of patients with chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 729-732.

Directly acting antiviral agents in hepatitis C

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments